{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:28:49Z","timestamp":1780439329774,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In heart failure with reduced ejection fraction (HFrEF), sodium\u2013glucose co-transporter inhibitors (SGLT-2i) have persistently shown cardiovascular benefits through different trials. However, their impact on ventricular remodeling and cardiac hemodynamics has not been sufficiently studied. This study aimed to study how SGLT-2i initiation affects invasive hemodynamics and cardiac magnetic resonance imaging (CMR)-derived ventricular volumes, function, and fraction of the extracellular volume (ECV) in HFrEF patients with non-ischemic dilated cardiomyopathy (NIDCM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this study, 23 patients with HFrEF and a mean age of 42, including 82.6% males, all have NIDCM and underwent right heart catheterization and CMR at the initiation of dapagliflozin and at 6-month follow-up. The addition of dapagliflozin resulted in significant reductions in the following invasive hemodynamic parameters compared to baseline: left ventricular end-diastolic pressure (23.4 vs 19.7 mmHg, <jats:italic>p<\/jats:italic>\u2009=\u20090.003), mean pulmonary artery pressure (31.3 vs 27.7 mmHg, <jats:italic>p<\/jats:italic>\u2009=\u20090.03), and systemic vascular resistance (18 vs 15 Wood units, <jats:italic>p<\/jats:italic>\u2009=\u20090.047). Among the studied CMR-derived measurements, only the percentage of extracellular volume fraction was significantly less at follow-up (33.7 vs 32.16%, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). Additionally, functional class showed significant improvement with a notable reduction of the NT-proBNP level and a considerable decrease in diuretic dose (median: 40 vs 80 mg, <jats:italic>p<\/jats:italic>\u2009=\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Adding dapagliflozin to patients with HFrEF due to NIDCM improved invasively measured hemodynamics and significantly reduced left ventricular extracellular volume fraction measured by CMR, with no significant change in ventricular volumes or ejection fraction.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-024-00508-z","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T15:04:05Z","timestamp":1718723045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ventricular remodeling and hemodynamic changes in heart failure patients with non-ischemic dilated cardiomyopathy following dapagliflozin initiation"],"prefix":"10.1186","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9797-4474","authenticated-orcid":false,"given":"Ahmed","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerollos","family":"Samaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Asfour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Baghdady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Anwar","family":"Samaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"issue":"21","key":"508_CR1","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMOA1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF Trial). N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMOA1911303","journal-title":"N Engl J Med"},{"issue":"12","key":"508_CR2","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMOA2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMOA2206286","journal-title":"N Engl J Med"},{"issue":"7","key":"508_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.009837","volume":"16","author":"ME Nassif","year":"2023","unstructured":"Nassif ME, Windsor SL, Gosch K et al (2023) Dapagliflozin improves heart failure symptoms and physical limitations across the full range of ejection fraction: pooled patient-level analysis from DEFINE-HF and PRESERVED-HF trials. Circ Heart Fail 16(7):e009837. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.122.009837","journal-title":"Circ Heart Fail"},{"issue":"5","key":"508_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/EURHEARTJ\/EHAB798","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Packer M, Filippatos G et al (2022) Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 43(5):416\u2013424. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB798","journal-title":"Eur Heart J"},{"issue":"15","key":"508_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMOA2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-reduced trial). N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMOA2022190","journal-title":"N Engl J Med"},{"issue":"21","key":"508_CR6","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT et al (2019) Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART cardiolink-6 randomized clinical trial. Circulation 140(21):1693\u20131702. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042375","journal-title":"Circulation"},{"issue":"6","key":"508_CR7","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1002\/EHF2.13626","volume":"8","author":"L Xu","year":"2021","unstructured":"Xu L, Pagano J, Chow K et al (2021) Cardiac remodelling predicts outcome in patients with chronic heart failure. ESC Heart Fail 8(6):5352. https:\/\/doi.org\/10.1002\/EHF2.13626","journal-title":"ESC Heart Fail"},{"issue":"9","key":"508_CR8","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/J.JCHF.2019.06.004","volume":"7","author":"A Aimo","year":"2019","unstructured":"Aimo A, Gaggin HK, Barison A, Emdin M, Januzzi JL (2019) Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction. JACC Heart Fail 7(9):782\u2013794. https:\/\/doi.org\/10.1016\/J.JCHF.2019.06.004","journal-title":"JACC Heart Fail"},{"issue":"1","key":"508_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12933-023-01970-W\/FIGURES\/4","volume":"22","author":"E Carluccio","year":"2023","unstructured":"Carluccio E, Biagioli P, Reboldi G et al (2023) Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies. Cardiovasc Diabetol 22(1):1\u201310. https:\/\/doi.org\/10.1186\/S12933-023-01970-W\/FIGURES\/4","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"508_CR10","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1002\/EHF2.13645","volume":"8","author":"NK Dhingra","year":"2021","unstructured":"Dhingra NK, Mistry N, Puar P et al (2021) SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials. ESC Heart Fail 8(6):4693\u20134700. https:\/\/doi.org\/10.1002\/EHF2.13645","journal-title":"ESC Heart Fail"},{"issue":"15","key":"508_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMOA2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMOA2022190","journal-title":"N Engl J Med"},{"issue":"16","key":"508_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMOA2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMOA2107038","journal-title":"N Engl J Med"},{"key":"508_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2022.917761","author":"H Wang","year":"2022","unstructured":"Wang H, Ding L, Tian L, Tian Y, Liao L, Zhao J (2022) Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: a meta-analysis of clinical studies. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/FENDO.2022.917761","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"508_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJMOA1504720","volume":"13","author":"S Steiner","year":"2016","unstructured":"Steiner S (2016) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Zeitschrift fur Gefassmedizin 13(1):17\u201318. https:\/\/doi.org\/10.1056\/NEJMOA1504720","journal-title":"Zeitschrift fur Gefassmedizin"},{"issue":"6","key":"508_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/J.JACBTS.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S (2020) Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci 5(6):632\u2013644. https:\/\/doi.org\/10.1016\/J.JACBTS.2020.02.004","journal-title":"JACC Basic Transl Sci"},{"issue":"13","key":"508_CR16","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1136\/HEARTJNL-2020-318060","volume":"107","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Singh T, Newby DE, Singh J (2021) Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart 107(13):1032\u20131038. https:\/\/doi.org\/10.1136\/HEARTJNL-2020-318060","journal-title":"Heart"},{"issue":"7","key":"508_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","volume":"20","author":"M Packer","year":"2023","unstructured":"Packer M (2023) SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nat Rev Cardiol 20(7):443\u2013462. https:\/\/doi.org\/10.1038\/s41569-022-00824-4","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"508_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/DOM.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW (2018) Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabet Obes Metab 20(3):479\u2013487. https:\/\/doi.org\/10.1111\/DOM.13126","journal-title":"Diabet Obes Metab"},{"key":"508_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2022.800490","author":"J Tang","year":"2022","unstructured":"Tang J, Ye L, Yan Q, Zhang X, Wang L (2022) Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism. Front Pharmacol. https:\/\/doi.org\/10.3389\/FPHAR.2022.800490","journal-title":"Front Pharmacol"},{"issue":"3","key":"508_CR20","doi-asserted-by":"publisher","first-page":"E009156","DOI":"10.1161\/CIRCHEARTFAILURE.121.009156","volume":"15","author":"M Omar","year":"2022","unstructured":"Omar M, Jensen J, Burkhoff D et al (2022) Effect of empagliflozin on blood volume redistribution in patients with chronic heart failure and reduced ejection fraction: an analysis from the empire HF randomized clinical trial. Circ Heart Fail 15(3):E009156. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.009156","journal-title":"Circ Heart Fail"},{"key":"508_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-020-01175-5","author":"M Rau","year":"2021","unstructured":"Rau M, Thiele K, Hartmann NUK et al (2021) Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Cardiovasc Diabetol. https:\/\/doi.org\/10.1186\/S12933-020-01175-5","journal-title":"Cardiovasc Diabetol."},{"issue":"9","key":"508_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/J.JACC.2020.06.069","volume":"76","author":"M Guazzi","year":"2020","unstructured":"Guazzi M, Ghio S, Adir Y (2020) Pulmonary hypertension in HFpEF and HFrEF: JACC review topic of the week. J Am Coll Cardiol 76(9):1102\u20131111. https:\/\/doi.org\/10.1016\/J.JACC.2020.06.069","journal-title":"J Am Coll Cardiol"},{"key":"508_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010042","author":"I Mustapic","year":"2023","unstructured":"Mustapic I, Bakovic D, SusilovicGrabovac Z, Borovac JA (2023) Impact of SGLT2 inhibitor therapy on right ventricular function in patients with heart failure and reduced ejection fraction. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12010042","journal-title":"J Clin Med"},{"issue":"17","key":"508_CR24","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL et al (2021) Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation 143(17):1673\u20131686. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052503","journal-title":"Circulation"},{"issue":"18","key":"508_CR25","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","volume":"139","author":"R Nielsen","year":"2019","unstructured":"Nielsen R, M\u00f8ller N, Gormsen LC et al (2019) Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation 139(18):2129\u20132141. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036459","journal-title":"Circulation"},{"issue":"5","key":"508_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/J.JACBTS.2019.04.003","volume":"4","author":"RP Juni","year":"2019","unstructured":"Juni RP, Kuster DWD, Goebel M et al (2019) Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin. JACC Basic Transl Sci 4(5):575\u2013591. https:\/\/doi.org\/10.1016\/J.JACBTS.2019.04.003","journal-title":"JACC Basic Transl Sci"},{"key":"508_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-018-23420-4","author":"SJ Mancini","year":"2018","unstructured":"Mancini SJ, Boyd D, Katwan OJ et al (2018) Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep. https:\/\/doi.org\/10.1038\/S41598-018-23420-4","journal-title":"Sci Rep"},{"issue":"1","key":"508_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-48716-y","volume":"13","author":"HH Kuo","year":"2023","unstructured":"Kuo HH, Lai YH, Lin PL et al (2023) Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus. Sci Rep 13(1):1\u20138. https:\/\/doi.org\/10.1038\/s41598-023-48716-y","journal-title":"Sci Rep"},{"key":"508_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-019-0910-5","author":"BM Bonora","year":"2019","unstructured":"Bonora BM, Vigili De Kreutzenberg S, Avogaro A, Fadini GP (2019) Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. Cardiovasc Diabetol. https:\/\/doi.org\/10.1186\/S12933-019-0910-5","journal-title":"Cardiovasc Diabetol"},{"issue":"23","key":"508_CR30","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","volume":"76","author":"M Omar","year":"2020","unstructured":"Omar M, Jensen J, Frederiksen PH et al (2020) Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 76(23):2740\u20132751. https:\/\/doi.org\/10.1016\/j.jacc.2020.10.005","journal-title":"J Am Coll Cardiol"},{"key":"508_CR31","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","volume":"35","author":"JN Cohn","year":"2000","unstructured":"Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling\u2013concepts and clinical implications: a consensus paper from an international forum on cardiac re-modeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 35:569\u2013582","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"508_CR32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","volume":"56","author":"DG Kramer","year":"2010","unstructured":"Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE (2010) Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 56(5):392\u2013406. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.011","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"508_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.2337\/DC19-2187","volume":"43","author":"JSS Singh","year":"2020","unstructured":"Singh JSS, Mordi IR, Vickneson K et al (2020) Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the reform trial. Diabetes Care 43(6):1356\u20131359. https:\/\/doi.org\/10.2337\/DC19-2187","journal-title":"Diabetes Care"},{"issue":"7","key":"508_CR34","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/JAMACARDIO.2020.6827","volume":"6","author":"M Omar","year":"2021","unstructured":"Omar M, Jensen J, Ali M et al (2021) Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial. JAMA Cardiol 6(7):836\u2013840. https:\/\/doi.org\/10.1001\/JAMACARDIO.2020.6827","journal-title":"JAMA Cardiol"},{"issue":"1","key":"508_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-021-01390-8","volume":"20","author":"B Sarak","year":"2021","unstructured":"Sarak B et al (2021) Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovasc Diabetol 20(1):1\u201311","journal-title":"Cardiovasc Diabetol"},{"key":"508_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.009535","author":"EY Yang","year":"2019","unstructured":"Yang EY, Ghosn MG, Khan MA et al (2019) Myocardial extracellular volume fraction adds prognostic information beyond myocardial replacement fibrosis. Circ Cardiovasc Imaging. https:\/\/doi.org\/10.1161\/CIRCIMAGING.119.009535","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"508_CR37","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/J.JCMG.2020.10.017","volume":"14","author":"T Mason","year":"2021","unstructured":"Mason T, Coelho-Filho OR, Verma S et al (2021) Empagliflozin reduces myocardial extracellular volume in patients with type 2 diabetes and coronary artery disease. JACC Cardiovasc Imaging 14(6):1164\u20131173. https:\/\/doi.org\/10.1016\/J.JCMG.2020.10.017","journal-title":"JACC Cardiovasc Imaging"},{"key":"508_CR38","doi-asserted-by":"crossref","unstructured":"Wang H DLTLTYLLZJ (2022) Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: a meta-analysis of clinical studies. Front Endocrinol (Lausanne). Published online 2022","DOI":"10.3389\/fendo.2022.917761"},{"issue":"6","key":"508_CR39","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K et al (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143(6):516\u2013525. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052186","journal-title":"Circulation"},{"key":"508_CR40","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2187","author":"JSS Singh","year":"2020","unstructured":"Singh JSS, Mordi IR, Vickneson K et al (2020) Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the Reform trial. Diabetes Care. https:\/\/doi.org\/10.2337\/dc19-2187","journal-title":"Diabetes Care"},{"issue":"112","key":"508_CR41","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.jcmg.2019.06.031","volume":"12","author":"AA Robinson","year":"2019","unstructured":"Robinson AA, Chow K, Salerno M (2019) Myocardial T1 and ECV measurement: underlying concepts and technical considerations. JACC Cardiovasc Imaging 12(112):2332\u20132344. https:\/\/doi.org\/10.1016\/j.jcmg.2019.06.031","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"508_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","volume":"141","author":"MN Kosiborod","year":"2020","unstructured":"Kosiborod MN, Jhund PS, Docherty KF et al (2020) Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation 141(2):90\u201399. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044138","journal-title":"Circulation"},{"key":"508_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042929","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor S, Tang F et al (2019) Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042929","journal-title":"Circulation"},{"issue":"5","key":"508_CR44","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ejhf.1432","volume":"21","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, DeMets DL, Inzucchi SE et al (2019) A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 21(5):665\u2013675. https:\/\/doi.org\/10.1002\/ejhf.1432","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"508_CR45","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/J.CHEST.2018.08.1033","volume":"154","author":"AR Hemnes","year":"2018","unstructured":"Hemnes AR, Opotowsky AR, Assad TR et al (2018) Features associated with discordance between pulmonary arterial wedge pressure and left ventricular end diastolic pressure in clinical practice: implications for pulmonary hypertension classification. Chest 154(5):1099. https:\/\/doi.org\/10.1016\/J.CHEST.2018.08.1033","journal-title":"Chest"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-024-00508-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-024-00508-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-024-00508-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T15:08:19Z","timestamp":1718723299000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-024-00508-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["508"],"URL":"https:\/\/doi.org\/10.1186\/s43044-024-00508-z","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"4 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and the informed consent form were revised and approved by the research ethics committee, Faculty of Medicine, Cairo University under registration number (MD-405\u20132021). [Research ethics committee reference:\u2009+\u20090201201730249; kasralainyrec@gmail.com] Written informed consents were acquired from all study participants.<b>Consent for publication<\/b>Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None of the authors have competing or conflicting interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}